A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05643495 |
Recruitment Status :
Active, not recruiting
First Posted : December 8, 2022
Last Update Posted : April 24, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Alpha-1 Antitrypsin Deficiency | Drug: VX-864 | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 20 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2, Open-label Study Evaluating Efficacy and Safety of VX-864 in Subjects With Alpha-1 Antitrypsin Deficiency Who Have the PiZZ Genotype, Over 48 Weeks |
Actual Study Start Date : | February 23, 2023 |
Estimated Primary Completion Date : | November 2024 |
Estimated Study Completion Date : | December 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Group A
Participants will receive VX-864 every 12 hours (q12h) for 48 weeks.
|
Drug: VX-864
Tablets for oral administration. |
Experimental: Group B
Participants will undergo a liver biopsy done before receiving VX-864 q12h for 48 weeks, and will undergo a second liver biopsy at either Week 24 or Week 48.
|
Drug: VX-864
Tablets for oral administration. |
- Change in Blood Functional Alpha-1 Antitrypsin (AAT) Levels [ Time Frame: From Baseline at Week 48 ]
- Change in Blood Functional AAT Levels [ Time Frame: From Baseline up to Week 48 ]
- Change in Blood Antigenic AAT Levels [ Time Frame: From Baseline up to Week 48 ]
- Change in Blood Z-polymer Levels [ Time Frame: From Baseline up to Week 48 ]
- Part B: Change in Z-polymer Accumulation in the Liver [ Time Frame: From Baseline up to Week 48 ]
- Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Day 1 up to Week 52 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Participants must have a PiZZ genotype confirmed at screening
- Plasma AAT levels indicating severe deficiency at screening
Key Exclusion Criteria:
- History of a medical condition that could negatively impact the ability to complete the study
- Solid organ, or hematological transplantation or is currently on a transplant list
- History of use of gene therapy or Ribonucleic acid interference (RNAi) therapy at any time previously
- Participants for whom discontinuation of augmentation therapy is not considered to be in their best interest, based on the clinical judgement of the treating physician
Other protocol defined Inclusion/Exclusion criteria may apply.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05643495
United States, Florida | |
University of Florida | |
Gainesville, Florida, United States, 32610 | |
Central Florida Pulmonary Group, P.A. | |
Orlando, Florida, United States, 32803 | |
United States, Iowa | |
The University of Iowa Hospitals and Clinics: Adult Pulmonary Clinic | |
Iowa City, Iowa, United States, 52242 | |
United States, Kansas | |
University of Kansas Medical Center | |
Kansas City, Kansas, United States, 66160 | |
United States, Missouri | |
Hannibal Regional Healthcare System | |
Hannibal, Missouri, United States, 63401 | |
United States, New York | |
Columbia University Irving Medical Center | |
New York, New York, United States, 10032 | |
United States, North Carolina | |
Marsico Clinical Research Center at UNC Pulmonary Clinic | |
Chapel Hill, North Carolina, United States, 27517 | |
United States, Texas | |
Renovatio Clinical | |
Houston, Texas, United States, 77380 | |
United States, Utah | |
University of Utah Health | |
Salt Lake City, Utah, United States, 84108 | |
United States, Virginia | |
Inova Fairfax Medical Campus | |
Falls Church, Virginia, United States, 22042 | |
Germany | |
University Hospital RWTH Aachen | |
Aachen, Germany | |
Ireland | |
Royal College of Surgeons in Ireland Clinical Research Centre, Beaumont Hospital | |
Beaumont, Ireland | |
United Kingdom | |
King's College Hospital | |
London, United Kingdom |
Responsible Party: | Vertex Pharmaceuticals Incorporated |
ClinicalTrials.gov Identifier: | NCT05643495 |
Other Study ID Numbers: |
VX22-864-108 2022-002746-40 ( EudraCT Number ) |
First Posted: | December 8, 2022 Key Record Dates |
Last Update Posted: | April 24, 2024 |
Last Verified: | October 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Alpha 1-Antitrypsin Deficiency Liver Diseases Digestive System Diseases Lung Diseases Respiratory Tract Diseases |
Genetic Diseases, Inborn Subcutaneous Emphysema Emphysema Pathologic Processes |